Skip to main content

Advertisement

Springer Nature Link
Log in

Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Non-small cell lung cancer (NSCLC) is an intractable disease for which effective treatment approaches are urgently needed. The ability to induce antigen-specific immune responses in patients with lung cancer has led to the development of immunotherapy as a novel concept for the treatment of NSCLC. Adoptive cellular therapy (ACT) represents an important advancement in cancer immunotherapy with the utilization of tumor infiltrating lymphocytes, cytokine-induced killer cells, natural killer cells and γδ T cells. In this study, we review recent advances in ACT for NSCLC in clinical trials and provide a perspective on the improvement in ACT and potential therapeutic approaches using engineered T cell therapy for NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29

    Article  PubMed  Google Scholar 

  2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4):220–241. doi:10.3322/caac.21149

    Article  PubMed  Google Scholar 

  3. Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, Vignaud J-M (2002) Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 140(5):320–328

    Article  PubMed  Google Scholar 

  4. Kuo SH, Chang DB, Lee YC, Lee YT, Luh KT (1998) Tumour-infiltrating lymphocytes in non-small cell lung cancer are activated T lymphocytes. Respirology 3(1):55–59

    Article  CAS  PubMed  Google Scholar 

  5. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund L-T (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14(16):5220–5227

    Article  CAS  PubMed  Google Scholar 

  6. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, Patz EF Jr (2006) Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107(12):2866–2872. doi:10.1002/cncr.22282

    Article  PubMed  Google Scholar 

  7. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168(9):4272–4276

    Article  CAS  PubMed  Google Scholar 

  8. H-y Fu, Li C, Yang W, Gai X-d, Jia T, Lei Y-m, Li Y (2013) FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape. Acta Histochem 115(2):151–157

    Article  Google Scholar 

  9. Zheng Y-W, Li R-M, Zhang X-W, Ren X-B (2013) Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest 31(3):197–205

    Article  CAS  PubMed  Google Scholar 

  10. Medzhitov R, Janeway Jr. CA (1998) Innate immune recognition and control of adaptive immune responses. In: Seminars in immunology. Elsevier, p 351–353

  11. Shi H, Liu L, Wang Z (2013) Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer Lett 328(2):191–197

    Article  CAS  PubMed  Google Scholar 

  12. Melioli G, Meta M, Semino C, Casartelli G, Pasquetti W, Biassoni R, Ratto G, Catrullo A, Moretta L, Guastella M (1994) Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: functional and molecular characterisation for their use in adoptive immunotherapy. Eur J Cancer 30(1):97–102

    Article  Google Scholar 

  13. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26(4):332 (Hagerstown, Md: 1997)

    Article  PubMed Central  PubMed  Google Scholar 

  14. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550–4557

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Ratto GB, Zino P, Mirabelli S, Minuti P, Aquilina R, Fantino G, Spessa E, Ponte M, Bruzzi P, Melioli G (1996) A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer 78(2):244–251

  16. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE (2010) CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 16(24):6122–6131

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Ye Q, Song D, Poussin M, Yamamoto T, Best A, Li C, Coukos G, Powell DJ (2014) CD137 accurately identifies and enriches for naturally-occurring tumor-reactive T cells in tumor. Clin Cancer Res 20:44–55

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Carding SR, Egan PJ (2002) γδ T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2(5):336–345

    Article  CAS  PubMed  Google Scholar 

  19. Hayday AC (2000) γδ cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18(1):975–1026

    Article  CAS  PubMed  Google Scholar 

  20. Yoshida Y, Nakajima J, Wada H, Kakimi K (2011) γδ T-cell immunotherapy for lung cancer. Surg Today 41(5):606–611

    Article  PubMed  Google Scholar 

  21. Dhillon S, Lyseng-Williamson KA (2008) Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs 68(4):507–534

    Article  CAS  PubMed  Google Scholar 

  22. Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H, Kakimi K (2011) Expansion of human peripheral blood γδ T cells using zoledronate. J Vis Exp (55):e3182. doi:10.3791/3182

  23. Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H, Kakimi K (2011) Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study. J Immunother 34(2):202–211. doi:10.1097/CJI.0b013e318207ecfb

    Article  CAS  PubMed  Google Scholar 

  24. Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, Takamoto S, Kakimi K (2010) A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells. Eur J Cardiothorac Surg 37(5):1191–1197

    Article  PubMed  Google Scholar 

  25. Kang N, Zhou J, Zhang T, Wang L, Lu F, Cui Y, Cui L, He W (2009) Adoptive immunotherapy of lung cancer with immobilized anti-TCRγδ antibody-expanded human γδ T Cells in peripheral blood. Cancer Biol Ther 8(16):1540–1549

    Article  CAS  PubMed  Google Scholar 

  26. Hanagiri T, Shigematsu Y, Kuroda K, Baba T, Shiota H, Ichiki Y, Nagata Y, Yasuda M, So T, Takenoyama M (2012) Antitumor activity of human γδ T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes. Cancer science 103(8):1414–1419

    Article  CAS  PubMed  Google Scholar 

  27. Parham P (2004) Immunology: NK cells lose their inhibition. Sci Signal 305(5685):786

    CAS  Google Scholar 

  28. Farag SS, Caligiuri MA (2006) Human natural killer cell development and biology. Blood Rev 20(3):123–137

    Article  CAS  PubMed  Google Scholar 

  29. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331(6013):44–49

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA (2010) A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 59(12):1781–1789

    Article  PubMed  Google Scholar 

  31. Schneider T, Kimpfler S, Warth A, Schnabel PA, Dienemann H, Schadendorf D, Hoffmann H, Umansky V (2011) Foxp3+ regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 6(3):432

    Article  PubMed  Google Scholar 

  32. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8):3051–3057

    Article  CAS  PubMed  Google Scholar 

  33. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Sci Signal 295(5562):2097

    CAS  Google Scholar 

  34. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA (2011) Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17(19):6287–6297

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7(5):329–339

    Article  CAS  PubMed  Google Scholar 

  36. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L (2008) Natural killer cell–directed therapies: moving from unexpected results to successful strategies. Nat Immunol 9(5):486–494

    Article  CAS  PubMed  Google Scholar 

  37. Cheng M, Chen Y, Xiao W, Sun R, Tian Z (2013) NK cell-based immunotherapy for malignant diseases. Cell mol immunol 10(3):230–252

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Jiang J, Wu C, Lu B (2013) Cytokine-induced killer cells promote antitumor immunity. J Transl Med 11(1):83

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Lu P-H, Negrin RS (1994) A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153(4):1687–1696

    CAS  PubMed  Google Scholar 

  40. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IGH (2011) Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137(2):305–310

    Article  CAS  PubMed  Google Scholar 

  41. Schmidt-Wolf I, Lefterova P, Mehta B, Fernandez L, Huhn D, Blume K, Weissman I, Negrin R (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21(13):1673

    CAS  PubMed  Google Scholar 

  42. Kim HM, Lim J, Park SK, Kang JS, Lee K, Lee CW, Lee KH, Yun MJ, Yang KH, Han G (2007) Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol 7(13):1802–1807

    Article  CAS  PubMed  Google Scholar 

  43. Liu L, Sun M, Wang Z (2012) Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors. Cancer Lett 316(1):1–5

    Article  CAS  PubMed  Google Scholar 

  44. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS (2005) A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11(3):181–187

    Article  PubMed  Google Scholar 

  45. Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, Han Y, Ren X (2009) Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 11(8):1076–1083

    Article  CAS  PubMed  Google Scholar 

  46. Yang L, Ren B, Li H, Yu J, Cao S, Hao X, Ren X (2012) Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 62(1):65–73

    Article  PubMed  Google Scholar 

  47. Shi SB, Ma TH, Li CH, Tang XY (2012) Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 98(3):314

    CAS  PubMed  Google Scholar 

  48. Shi S, Wang R, Chen Y, Song H, Chen L, Huang G (2013) Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS ONE 8(6):e65757

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Chiriva-Internati M, Pandey A, Saba R, Kim M, Saadeh C, Lukman T, Chiaramonte R, Jenkins M, Cobos E, Jumper C (2012) Cancer testis antigens: a novel target in lung cancer. Int Rev Immunol 31(5):321–343

    Article  CAS  PubMed  Google Scholar 

  50. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29(7):917–924

    Article  PubMed Central  PubMed  Google Scholar 

  51. Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187(8):1349–1354

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC (2007) Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 120(2):337–343

    Article  CAS  PubMed  Google Scholar 

  53. Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang M, Xi S, Liu F, Marquez VE, Morgan RA, Schrump DS (2011) Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res 71(12):4192–4204

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer J Int du Cancer 119(2):243–250. doi:10.1002/ijc.21712

    Article  CAS  Google Scholar 

  55. O’Shannessy DJ, Yu G, Smale R, Fu Y-S, Singhal S, Thiel RP, Somers EB, Vachani A (2012) Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 3(4):414

    PubMed Central  PubMed  Google Scholar 

  56. Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W (2012) High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR mutation. J Thorac Oncol 7(5):833

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Cagle PT, Zhai QJ, Murphy L, Low PS (2013) Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents. Arch Pathol Lab Med 137(2):241–244

    Article  CAS  PubMed  Google Scholar 

  58. Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ (2011) In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 71(13):4617–4627

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr (2012) CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119(3):696–706

    Article  CAS  PubMed  Google Scholar 

  60. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan D-AN, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19(3):620–626

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843–851

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Casucci M, Bondanza A (2011) Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes. J Cancer 2:378

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365(18):1673–1683

    Article  PubMed Central  PubMed  Google Scholar 

  64. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL (2010) Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70(22):9053–9061

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM (2014) Mesothelin-specific chimeric antigen receptor mrna-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res 2:112–120

Download references

Conflict of interest

No potential conflicts of interest were disclosed.

Author information

Authors and Affiliations

  1. Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun, 130021, Jilin, People’s Republic of China

    Junying Wang

  2. Department of Pathology, The Third Hospital of Jilin University, Changchun, 130033, Jilin, People’s Republic of China

    Xueju Wang

Authors
  1. Junying Wang
    View author publications

    Search author on:PubMed Google Scholar

  2. Xueju Wang
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Junying Wang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Wang, X. Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer. Mol Biol Rep 41, 6317–6323 (2014). https://doi.org/10.1007/s11033-014-3514-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3514-x

Keywords